Outcomes of Pediatric Patients with Malignancies of the Major Salivary Glands

Kupferman, Michael E.; Garza, Gabriel O. de la; Santillan, Alfredo A.; Williams, Michelle D.; Varghese, Bipin T.; Huh, Winston W.; Roberts, Dianna B.; Weber, Randal S.

doi:10.1245/s10434-010-1165-2

Cited by 81 publications

(111 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, the most common histological type is MEC. It is reported that survival of pediatric patients with major salivary gland carcinomas is generally favorable with a 5-year overall survival of over 90 % [6].…”

Section: Discussionmentioning

confidence: 99%

Mammary Analogue Secretory Carcinoma of the Parotid Gland as a Secondary Malignancy in a Childhood Survivor of Atypical Teratoid Rhabdoid Tumor

Woo

Seethala

Sirintrapun

2013

Head and Neck Pathol

View full text Add to dashboard Cite

We report the first case of mammary analogue secretory carcinoma (MASC) arising as a secondary malignancy in a 14 years old child with a history of atypical teratoid rhabdoid tumor (ATRT). Although MASC and ATRT are both rare malignancies, they do not share the same genetic and molecular profiles. MASC is a salivary malignancy characterized by a t(12;15)(p13;q25) translocation, resulting in an ETV6-NTRK3 fusion product encoding for a tyrosine kinase. ATRT is a highly malignant pediatric tumor characterized by a chromosome 22 mutation in the hSNF5/INI1 gene, encoding for a chromatin remodeling protein. Additionally, although mucoepidermoid carcinoma has been described as a secondary malignancy post-therapy for head and neck tumors, MASC has only been reported as a primary malignancy. Our patient was treated with a complete resection of his left sided ATRT at age 3 followed postoperatively with chemoradiotherapy. At age 14 he underwent a parotidectomy for his 1 year history of a left sided preauricular mass and was subsequently diagnosed with MASC. We not only report a case of two rare malignancies in one patient, but also the first case of MASC arising as a secondary malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Mammary Analogue Secretory Carcinoma of the Parotid Gland as a Secondary Malignancy in a Childhood Survivor of Atypical Teratoid Rhabdoid Tumor

Woo

Seethala

Sirintrapun

2013

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…Superficial or lateral parotidectomy for a laterally located tumour mass is the typical procedure. Total parotidectomy may be required for deep lobe or parapharyngeal tumour mass lesions [27] or when the tumour mass is suspected or confirmed to be high grade or to have aggressive malignant potential, such as a mass presenting with a facial nerve palsy, multiple intraparotid masses, or a mass coupled with the presence of cervical metastasis [2,5,6,16,20,[31][32][33] . Resection of the facial nerve is currently recommended when there is gross anatomic or histological evidence of nerve invasion at the time of surgery.…”

Section: Parotid Glandmentioning

confidence: 99%

“…Radiation therapy is beneficial for loco-regional control of disease, with acceptable long-term treatment sequelae and without significant risk of developing second primary tumours. The overall survival is 70-90% at 5 years, and 26% develop a recurrence [5,6,20,22,31,32,35,37] . Paediatric salivary gland cancer patients are at a 3% risk of developing a second cancer within 20 years after completion of treatment of the primary malignancy.…”

Section: Outcomementioning

confidence: 99%

Salivary Gland Neoplasms in Children and Adolescents

Bradley

Eisele

2016

Salivary Gland Neoplasms

View full text Add to dashboard Cite

Salivary gland neoplasms (SGNs) in children are uncommon. Epithelial SGNs (ESGNs) comprise the majority (95%), with the remaining being mesenchymal SGNs (MeSGNs). Pleomorphic adenoma is the most frequently encountered benign neoplasm, mucoepidermoid carcinoma is the most frequent malignant ESGN, and rhabdomyosarcoma is the most frequent malignant MeSGN. ESGN presents in the second decade, whereas MeSGN presents in the first and second decades. Swelling without pain or neurological signs is the main presentation of both benign and malignant neoplasms. Making an accurate preoperative histological diagnosis is important, so a needle biopsy or a perioperative frozen section is useful when there is doubt about the disease status of the patient; the excised tumour margin is also important. Surgical excision should aim to achieve clear margin excision in benign and malignant ESGNs, minimising the need for adjuvant radiotherapy and maximising the long-term likelihood of patient cure. Benign ESGNs are uncommon, and excision is curative, whereas malignant ESGN and MeSGN should be managed by a multidisciplinary paediatric oncology team.

show abstract

“…About half of such tumors are malignant [2–4], and most are well to moderately differentiated without nodal involvement or distant metastasis [5, 6]. The 5–year survival rates for pediatric patients with malignant salivary gland tumors range from 85% to 98% [1, 6, 7]. …”

Section: Introductionmentioning

confidence: 99%

Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics

Grant

Grosshans

Bilton

et al. 2015

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

Purpose We evaluated acute toxicity profiles and dosimetric data for children with salivary gland tumors treated with adjuvant photon/electron-based radiation therapy (X/E RT) or proton therapy (PRT). Methods and Materials We identified 24 patients who had received adjuvant radiotherapy for salivary gland tumors. Data was extracted from the medical records and the treatment planning systems. Toxicity was scored according to the Common Terminology Criteria for Adverse Effects 4.0. Results Eleven patients received X/E RT and 13 PRT, with a median prescribed dose of 60 Gy in each group. In the X/E RT group, 54% of patients developed acute grade II/III dermatitis, 27% grade II/III dysphagia, and 91% grade II/III mucositis, and the median weight loss was 5.3% with one patient requiring feeding tube placement. In the PRT group, 53% had acute grade II/III dermatitis, 0% grade II/III dysphagia, and 46% grade II/III mucositis, with a median weight gain of 1.2%. Additionally, PRT was associated with lower mean doses to several normal surrounding midline and contralateral structures. Conclusion In this retrospective study of pediatric salivary tumors, PRT was associated with a favorable acute toxicity and dosimetric profile. Continued follow-up is needed to identify long-term toxicity and survival data.

show abstract

Outcomes of Pediatric Patients with Malignancies of the Major Salivary Glands

Cited by 81 publications

References 20 publications

Mammary Analogue Secretory Carcinoma of the Parotid Gland as a Secondary Malignancy in a Childhood Survivor of Atypical Teratoid Rhabdoid Tumor

Mammary Analogue Secretory Carcinoma of the Parotid Gland as a Secondary Malignancy in a Childhood Survivor of Atypical Teratoid Rhabdoid Tumor

Salivary Gland Neoplasms in Children and Adolescents

Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics

Contact Info

Product

Resources

About